Gemcitabine, Etoposide, Cisplatin, and Dexamethasone in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
Ki-Hyang Kim, Young-Don Joo, Chang-Hak Sohn, Ho-Jin Shin, Joo-Seop Chung, Goon-Jae Cho, Sung-Hoon Shin, Yang-Soo Kim, Won-Sik Lee
Korean J Intern Med. 2009;24(1):37-42. Published online 2009 Mar 6 DOI: https://doi.org/10.3904/kjim.2009.24.1.37
Citations to this article as recorded by 
Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial
Jae-Cheol Jo, Jin Ho Baek, Je-Hwan Lee, Young-Don Joo, Sung-Hwa Bae, Jung-Lim Lee, Jung-Hee Lee, Dae-Young Kim, Won-Sik Lee, Hun Mo Ryoo, Yunsuk Choi, Hawk Kim, Kyoo-Hyung Lee
Asia-Pacific Journal of Clinical Oncology.2016; 12(2): 159. CrossRef
Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
Jing-hua Wang, Hua Wang, Yan-jun Wang, Zhong-jun Xia, Hui-qiang Huang, Wen-qi Jiang, Yue Lu
Oncotarget.2016; 7(23): 35412. CrossRef
Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrosp
Hua Wang, Zhi-Jun Wuxiao, Jiayu Zhu, Zhihui Wang, Ke-Feng Wang, Su Li, Xiaoqin Chen, Yue Lu, Zhong-Jun Xia
Leukemia & Lymphoma.2015; 56(4): 971. CrossRef
Clinical Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Literature Review
Ann Colosia, Annete Njue, Peter C. Trask, Robert Olivares, Shahnaz Khan, Adeline Abbe, Rachel Police, Jianmin Wang, Rodrigo Ruiz-Soto, James A. Kaye, Farrukh Awan
Clinical Lymphoma Myeloma and Leukemia.2014; 14(5): 343. CrossRef
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center
Jan-Henrik Mikesch, Mareike Kuhlmann, Angela Demant, Utz Krug, Gabriela B. Thoennissen, Eva Schmidt, Torsten Kessler, Christoph Schliemann, Michele Pohlen, Michael Mohr, Georg Evers, Gabriele Köhler, Johannes Wessling, Rolf Mesters, Carsten Müller-Tidow,
Annals of Hematology.2013; 92(8): 1041. CrossRef
First‐line combination of gemcitabine, oxaliplatin, and L‐asparaginase (GELOX) followed by involved‐field radiation therapy for patients with stage IE/IIE extranodal natural killer/T‐cell lymphoma
Liang Wang, Zhi‐hui Wang, Xiao‐qin Chen, Ya‐jun Li, Ke‐feng Wang, Yun‐fei Xia, Zhong‐jun Xia
Cancer.2013; 119(2): 348. CrossRef
Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma
Yun Hou, Hua-qing Wang, Yi Ba
Medical Oncology.2012; 29(4): 2409. CrossRef